IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1378 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  Next article
  Previous article 
  Table of Contents
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (46 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   Sources

 Article Access Statistics
    Viewed3190    
    Printed152    
    Emailed0    
    PDF Downloaded180    
    Comments [Add]    

Recommend this journal

 
MOLECULES OF THE MILLENNIUM
Year : 2004  |  Volume : 36  |  Issue : 2  |  Page : 109
 

Rasburicase


Department of Pharmacology, Govt. Medical College, Amritsar - 143 001, India

Correspondence Address:
Department of Pharmacology, Govt. Medical College, Amritsar - 143 001, India
iraverma2000@yahoo.com



How to cite this article:
Sharma G, Verma I. Rasburicase. Indian J Pharmacol 2004;36:109


How to cite this URL:
Sharma G, Verma I. Rasburicase. Indian J Pharmacol [serial online] 2004 [cited 2019 Sep 21];36:109. Available from: http://www.ijp-online.com/text.asp?2004/36/2/109/6778


Rasburicase is a genetically engineered, recombinant form of urate oxidase enzyme that has recently been approved for use both in the United States and Europe, for the treatment and prophylaxis of hyperuricaemia associated with tumor lysis syndrome in pediatric patients. Rasburicase is made up of a single polypeptide chain with 301 amino acids and is produced from Saccharomyces cerevisiae.
Hyperuricaemia is a component of 'tumor lysis syndrome' which is a condition that occurs when patients with a high tumor burden (leukemias, lymphomas and solid tumor malignancies) are given chemotherapy. This secondary increase in uric acid levels can lead to acute renal failure which is a severe and potentially life-threatening condition.
The condition has been conventionally managed by giving the patient plenty of fluids, alkalization of urine and administration of allopurinol which may occasionally lead to an overload of uric acid precursors and cause xanthine nephropathy.
Rasburicase presents a new approach for managing secondary hyperuricaemia. Urate oxidase is an enzyme lacking in humans, but present normally in other mammals. It is responsible for rapidly converting the poorly soluble uric acid to highly soluble allantoin which is easily excreted by the kidneys.
Rasburicase is administered just before the start of chemotherapy. It is given as an IV infusion over a period of 30 minutes, in a dose of 0.15 - 0.2 mg/kg body weight, daily for 5 days. Chemotherapy is initiated 4-24 hours after the first dose of rasburicase. The lyophilized product and the diluent have to be stored at 2-8[0]C. The drug has a half-life of 19 hours and is metabolized by hydrolysis.
In clinical trials which compared rasburicase to allopurinol, the former reduced the concentration of uric acid significantly faster than allopurinol.
Attributable adverse effects seen with rasburicase were hypersensitivity reactions ranging from rashes, bronchospasm and hypotension to severe anaphylaxis. Other Grade 3 or 4 adverse events included fever, nausea, vomiting, diarrhea and headache. Rasburicase, being a protein, may stimulate the formation of antibodies against itself; it is also associated with methaemoglobinaemia. In patients with G-6PD deficiency, this drug can cause severe hemolysis.
The drug has only been approved for a single course of treatment. Further immunogenicity studies are underway to determine the impact of antibody formation and settle the issue of repeated use of rasburicase.


  Sources Top

http://www.fda.gov/cber/label/rasbsan071202LB.pdf
http://www.docguide.com/news/content.nsf/news/8525697700573E1885256BF90060D9F3 

Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow